PLUR
Pluri, Inc.
NASDAQ · Healthcare · Biotechnology · IL
$1.22
−3.94%Price chart
Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4
Key dataNov 4, 2026
Open$1.27
From 52W high−72.58%
Volume9431.00
Market cap$16.49M
P/E (TTM)—
P/S (TTM)16.2x
Div yield—
Key dataNov 4, 2026
Open
$1.27
From 52W high
−72.58%
Volume
9431.00
Market cap
$16.49M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−2.0x
P/E (TTM)
—
RSI (14)
57.8
MomentumView details →
1D Return
−3.94%
YTD Return
−59.20%
SummaryUpdated Jun 1, 2026
Pluri Inc. (NASDAQ:PLUR) is an Israeli biotechnology company founded in 2001 and headquartered in Haifa, Israel. Originally incorporated as Pluristem Therapeutics Inc., the company rebranded to Pluri Inc. in July 2022. The company went public in 2003 and has been developing innovative cell therapy treatments for over two decades. Pluri specializes in creating therapeutic products derived from placental cells, focusing on treating inflammatory conditions, muscle injuries, and blood-related disorders through its proprietary placental expanded (PLX) cell therapy platform.
Similar companies
Latest newsMore news →
Pluri Inc. entered into securities purchase agreements to sell 909,092 common shares at US$1.10 per share and warrants to purchase up to 909,092 additional shares at US$1.30 per share, for total proceeds of US$1 million; the offering was expected to close by October 30, 2026.5d agoZEO ScientifiX, Inc. and Pluri Inc. entered into a definitive strategic agreement to expand their U.S. manufacturing and commercialization platform for regenerative medicine, aesthetics, wellness, and longevity markets.9d ago